Efficacy and Safety of Teprotumumab in the Treatment of Thyroid Eye Disease Patients with Long Duration and Low Disease Activity
Published: 17 November 2023| Version 1 | DOI: 10.17632/x38yzs6cd3.1
Contributor:
Raymond DouglasDescription
SUPPLEMENT Efficacy and Safety of Teprotumumab in the Treatment of Thyroid Eye Disease Patients with Long Duration and Low Disease Activity: A Randomised Double-Masked, Placebo-controlled, Multicenter Trial Raymond S. Douglas et al
Files
Categories
Controlled Clinical Trial